ClinicalTrials.gg
Active, not recruitingNCT03706365CYCLONE 2Updated Aug 7, 2026Results posted

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

A Phase 2/3 interventional study of Abemaciclib and Placebo in Prostate Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 112 sites in 11 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.

Enrollment
2nd of 10
393 · median 15
Started
2018
the only one that year
Phase 2/3
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
4 of 10
Eli Lilly and Company

Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2018, is the only one in phase 2/3, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing abemaciclib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Metastatic Castration Resistant Prostate Cancer
  • mCRPC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate.
  • prostate cancer documented by positive bone scan and/or measurable soft tissue metastatic lesions by CT or magnetic resonance imaging (MRI).
  • Progressive disease at study entry demonstrated during continuous androgen-deprivation therapy (ADT)/post orchiectomy defined as one or more of the following:

    • PSA progression
    • Radiographic progression per (RECIST)1.1 for soft tissue and/or per Prostate Cancer Working Group 3 (PCWG3) for bone, with or without PSA progression
  • Have adequate organ function.
  • (ECOG) performance status (PS) 0-1.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with cytochrome P450 (CYP)17 inhibitors.
  • Prior treatment with abemaciclib or any cyclin-dependent kinase (CDK) 4 \& 6 inhibitors.
  • Prior cytotoxic chemotherapy for castration resistant prostate cancer (participants treated with docetaxel in the metastatic hormone-sensitive prostate cancer [mHSPC] are eligible). Prior radiopharmaceuticals for prostate cancer, or prior enzalutamide, apalutamide, darolutamide or sipuleucel-T. Participants who had prior radiation or surgery to all target lesions.
  • Currently enrolled in a clinical study involving an product.
  • Gastrointestinal disorder affecting the absorption or ability to swallow large pills.
  • heart disease, active or chronic liver disease, moderate/severe hepatic impairment ( Class B and C).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    Abemaciclib

    Participants received 200 milligrams (mg) abemaciclib twice daily (BID) in combination with standard doses of 1000 mg abiraterone acetate once daily and 5 mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.

    Drug: Abemaciclib · Drug: Abiraterone acetate · Drug: Prednisone

  • Placebo comparator
    Placebo

    Participants received placebo BID in combination with standard doses of 1000 mg abiraterone acetate once daily and 5 mg prednisone BID administered orally on a continuous dosing schedule on days 1 through 28 of a 28-day cycle until radiographic and/or symptomatic progression or until another discontinuation criterion is met.

    Drug: Placebo · Drug: Abiraterone acetate · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Radiographic Progression Free Survival (rPFS)

    The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

    Time frame: From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)

Secondary outcomes

  1. Time to Prostate-Specific Antigen (PSA) Progression

    The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.

    Time frame: From Date of Randomization to the Date of the First Observation of PSA Progression (Up to 60 Months)

  2. Radiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review

    rPFS is defined as the time from the date of randomization to the earliest date of radiographic disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.

    Time frame: From Date of Randomization Until Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)

  3. Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)

    ORR is a summary measure of best overall response (BOR) as defined by RECIST 1.1 for soft tissue per investigator assessment. BOR is derived from time point responses. All time point responses observed while on study treatment and during the short-term follow-up period (but before the initiation of post-discontinuation systemic anticancer therapy) will be included in the derivation. Each patient's BOR will be categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). A BOR of CR or PR will require confirmation, but sensitivity analyses of response-based endpoints may be performed where confirmation of a BOR of CR or PR is not required.

    Time frame: Baseline to Radiographic Disease Progression (Up to 60 Months)

  4. Duration of Response (DOR)

    The DoR time is defined only for responders (participants with a soft tissue BOR of CR or PR) in the measurable disease population. It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator determined radiographic disease progression or death from any cause, whichever is earlier.

    Time frame: Date of First Documented CR or PR to Date of Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)

  5. Overall Survival (OS)

    The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

    Time frame: From Date of Randomization to Date of Death Due to Any Cause (Up to 60 Months)

  6. Time to Symptomatic Progression

    Time to symptomatic progression is defined as the time from randomization to any of the following (whichever occurs earlier): 1. Symptomatic Skeletal Event (SSE), defined as symptomatic fracture, surgery or radiation to bone, or spinal cord compression. 2. Pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy. 3. Development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.

    Time frame: From Randomization to the Date of the First Documented Symptomatic Progression (Up to 60 Months)

  7. Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib

    PK: Mean steady state exposure of abemaciclib.

    Time frame: Cycle (C) 1 Day (D) 1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)

  8. PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567

    PK: Mean steady state exposure of abemaciclib metabolite LSN2839567.

    Time frame: C1 D1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)

  9. PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726

    PK: Mean steady state exposure of abemaciclib metabolite LSN3106726.

    Time frame: C1 D1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)

  10. PK: Mean Steady State Exposure of Abiraterone Acetate

    PK: Mean Steady State Exposure of Abiraterone Acetate.

    Time frame: C1 D15, Post dose

  11. Time to Worst Pain Progression

    Time to Worst Pain Progression defined as the time from randomization to any of the following (whichever occurs earlier): For participants without opioid use at baseline (World Health Organization-Analgesic Ladder-WHO-AL ≤ 2):- Worst pain progression (an increase of 2 points from baseline on the Worst Pain Numeric Rating Scale (NRS) item on 2 consecutive evaluations), Initiation of weak or strong opioids (WHO-AL ≥ 3); For participants with weak or strong opioid use at baseline (WHO-AL ≥ 3): Worst pain progression (an increase of 2 points from baseline on the Worst Pain NRS item on 2 consecutive evaluations) without concurrent decreased opioid use (a decrease in WHO-AL of 1 or more) -Increased opioid use (an increase in WHO-AL of 1 or more).

    Time frame: From Randomization Through Follow-up (Up to 60 months)

07

Results

Posted Mar 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclibPlacebo
Started206187
Received at least one dose of study drug206185
Completed131121
Not completed7566
Withdrew: Lost to follow-up70
Withdrew: Withdrawal by subject1715
Withdrew: On study treatment5151

Outcome measures

PrimaryRadiographic Progression Free Survival (rPFS)

The rPFS time is measured from the date of randomization to the earliest date of investigator determined radiographic disease progression (by objective radiographic disease assessment per response evaluation criteria in solid tumors (RECIST) version 1.1 for soft tissue AND/OR radionuclide bone scan using prostate cancer working group 3 -PCWG3 criteria for bone) or death from any cause, whichever occurs first.

Time frame:
From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)
Reported as:
Median · Months
Radiographic Progression Free Survival (rPFS)
MonthsAbemaciclibPlacebo
Radiographic Progression Free Survival (rPFS)21.96 (19.33 to 27.48)20.28 (16.47 to 24.36)
Statistical analysis
  • Abemaciclib vs Placebo · Log Rank · p = 0.2123 · Hazard ratio (hr): 0.829 · 95% CI 0.619 to 1.111
SecondaryTime to Prostate-Specific Antigen (PSA) Progression

The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.

Time frame:
From Date of Randomization to the Date of the First Observation of PSA Progression (Up to 60 Months)
Reported as:
Median · Months
Time to Prostate-Specific Antigen (PSA) Progression
MonthsAbemaciclibPlacebo
Time to Prostate-Specific Antigen (PSA) Progression22.19 (15.68 to 33.17)16.60 (12.03 to 20.28)
Statistical analysis
  • Abemaciclib vs Placebo · Log Rank · p = 0.0026 · Hazard ratio (hr): 0.637 · 95% CI 0.474 to 0.856
SecondaryRadiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review

rPFS is defined as the time from the date of randomization to the earliest date of radiographic disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.

Time frame:
From Date of Randomization Until Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)
Reported as:
Median · Months
Radiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review
MonthsAbemaciclibPlacebo
Radiographic Progression Free Survival (rPFS) Determined by Blinded Independent Central Review24.89 (21.96 to NA)22.88 (19.36 to 31.50)
Statistical analysis
  • Abemaciclib vs Placebo · Log Rank · p = 0.2899 · Hazard ratio (hr): 0.842 · 95% CI 0.611 to 1.160
SecondaryObjective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)

ORR is a summary measure of best overall response (BOR) as defined by RECIST 1.1 for soft tissue per investigator assessment. BOR is derived from time point responses. All time point responses observed while on study treatment and during the short-term follow-up period (but before the initiation of post-discontinuation systemic anticancer therapy) will be included in the derivation. Each patient's BOR will be categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). A BOR of CR or PR will require confirmation, but sensitivity analyses of response-based endpoints may be performed where confirmation of a BOR of CR or PR is not required.

Time frame:
Baseline to Radiographic Disease Progression (Up to 60 Months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)
percentage of participantsAbemaciclibPlacebo
Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR)45.2 (34.6 to 55.9)54.8 (43.4 to 66.2)
SecondaryDuration of Response (DOR)

The DoR time is defined only for responders (participants with a soft tissue BOR of CR or PR) in the measurable disease population. It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator determined radiographic disease progression or death from any cause, whichever is earlier.

Time frame:
Date of First Documented CR or PR to Date of Radiographic Disease Progression or Death from Any Cause (Up to 60 Months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsAbemaciclibPlacebo
Duration of Response (DOR)21.27 (16.60 to NA)15.68 (11.87 to 39.35)
Statistical analysis
  • Abemaciclib vs Placebo · Log Rank · p = 0.3531 · Hazard ratio (hr): 0.731 · 95% CI 0.377 to 1.419
SecondaryOverall Survival (OS)

The OS time is measured from the date of randomization to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

Time frame:
From Date of Randomization to Date of Death Due to Any Cause (Up to 60 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAbemaciclibPlacebo
Overall Survival (OS)38.01 (30.58 to 46.65)33.21 (29.52 to NA)
Statistical analysis
  • Abemaciclib vs Placebo · Log Rank · p = 0.6507 · Hazard ratio (hr): 0.927 · 95% CI 0.669 to 1.285
SecondaryTime to Symptomatic Progression

Time to symptomatic progression is defined as the time from randomization to any of the following (whichever occurs earlier): 1. Symptomatic Skeletal Event (SSE), defined as symptomatic fracture, surgery or radiation to bone, or spinal cord compression. 2. Pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy. 3. Development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.

Time frame:
From Randomization to the Date of the First Documented Symptomatic Progression (Up to 60 Months)
Reported as:
Median · Months
Time to Symptomatic Progression
MonthsAbemaciclibPlacebo
Time to Symptomatic Progression51.39 (27.98 to NA)35.74 (28.44 to NA)
Statistical analysis
  • Abemaciclib vs Placebo · Log Rank · p = 0.1807 · Hazard ratio (hr): 0.768 · 95% CI 0.522 to 1.131
SecondaryPharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib

PK: Mean steady state exposure of abemaciclib.

Time frame:
Cycle (C) 1 Day (D) 1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib
nanogram per milliliter (ng/mL)Abemaciclib
C1 D14.79 ± 157
C1 D15289 ± 58.7
C2 D1253 ± 65.7
C2 D15252 ± 68.4
C3 D1270 ± 54.5
SecondaryPK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567

PK: Mean steady state exposure of abemaciclib metabolite LSN2839567.

Time frame:
C1 D1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)
Reported as:
Geometric mean · ng/mL
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567
ng/mLAbemaciclib
C1 D12.90 ± 87.4
C1 D15125 ± 50.4
C2 D1112 ± 50.1
C2 D15116 ± 51.0
C3 D1110 ± 62.2
SecondaryPK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726

PK: Mean steady state exposure of abemaciclib metabolite LSN3106726.

Time frame:
C1 D1: Predose, 30 min post-dose; C1 D15, C2 D1, C2 D15, C3 D1: Post dose (28 Days Cycle)
Reported as:
Geometric mean · ng/mL
PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726
ng/mLAbemaciclib
C1 D12.80 ± 77.7
C1 D15195 ± 43.0
C2 D1174 ± 42.8
C2 D15174 ± 44.1
C3 D1176 ± 36.4
SecondaryPK: Mean Steady State Exposure of Abiraterone Acetate

PK: Mean Steady State Exposure of Abiraterone Acetate.

Time frame:
C1 D15, Post dose
Reported as:
Geometric mean · ng/mL
PK: Mean Steady State Exposure of Abiraterone Acetate
ng/mLAbemaciclibPlacebo
PK: Mean Steady State Exposure of Abiraterone Acetate45.2 ± 17540.0 ± 203
SecondaryTime to Worst Pain Progression

Time to Worst Pain Progression defined as the time from randomization to any of the following (whichever occurs earlier): For participants without opioid use at baseline (World Health Organization-Analgesic Ladder-WHO-AL ≤ 2):- Worst pain progression (an increase of 2 points from baseline on the Worst Pain Numeric Rating Scale (NRS) item on 2 consecutive evaluations), Initiation of weak or strong opioids (WHO-AL ≥ 3); For participants with weak or strong opioid use at baseline (WHO-AL ≥ 3): Worst pain progression (an increase of 2 points from baseline on the Worst Pain NRS item on 2 consecutive evaluations) without concurrent decreased opioid use (a decrease in WHO-AL of 1 or more) -Increased opioid use (an increase in WHO-AL of 1 or more).

Time frame:
From Randomization Through Follow-up (Up to 60 months)
Reported as:
Median · Months
Time to Worst Pain Progression
MonthsAbemaciclibPlacebo
Time to Worst Pain Progression41.49 (19.40 to NA)24.79 (19.17 to 31.46)
Statistical analysis
  • Abemaciclib vs Placebo · Log Rank · p = 0.6970 · Hazard ratio (hr): 0.935 · 95% CI 0.665 to 1.314

Adverse events

Collected over Baseline Up to 60 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib81/206 (39.3%)89/206 (43.2%)204/206 (99%)
Placebo72/187 (38.5%)66/185 (35.7%)176/185 (95.1%)
Most frequent serious events
Showing 10 of 156
Most frequent serious events
EventAbemaciclibPlacebo
Acute kidney injuryRenal and urinary disorders9/2061/185
AnaemiaBlood and lymphatic system disorders6/2063/185
DiarrhoeaGastrointestinal disorders6/2061/185
PneumoniaInfections and infestations6/2065/185
Covid-19Infections and infestations4/2060/185
Covid-19 pneumoniaInfections and infestations4/2061/185
UrosepsisInfections and infestations4/2060/185
DyspnoeaRespiratory, thoracic and mediastinal disorders4/2062/185
ColitisGastrointestinal disorders1/2063/185
ArthralgiaMusculoskeletal and connective tissue disorders1/2063/185
Most frequent other events
Showing 10 of 661
Most frequent other events
EventAbemaciclibPlacebo
DiarrhoeaGastrointestinal disorders134/20635/185
FatigueGeneral disorders107/20647/185
AnaemiaBlood and lymphatic system disorders91/20621/185
NauseaGastrointestinal disorders73/20627/185
Blood creatinine increasedInvestigations58/2061/185
NeutropeniaBlood and lymphatic system disorders57/2061/185
Decreased appetiteMetabolism and nutrition disorders50/20615/185
VomitingGastrointestinal disorders48/20617/185
Alanine aminotransferase increasedInvestigations48/20621/185
Back painMusculoskeletal and connective tissue disorders36/20642/185

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)AbemaciclibPlaceboTotal
Mean68.70 ± 8.5769.60 ± 8.8169.10 ± 8.69
Sex: Female, Male
Sex: Female, Male(Participants)AbemaciclibPlaceboTotal
Female000
Male206187393
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AbemaciclibPlaceboTotal
Hispanic or Latino13720
Not Hispanic or Latino186174360
Unknown or Not Reported7613
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AbemaciclibPlaceboTotal
American Indian or Alaska Native000
Asian354580
Native Hawaiian or Other Pacific Islander000
Black or African American71017
White161128289
More than one race101
Unknown or Not Reported246
Region of Enrollment
Region of Enrollment(participants)AbemaciclibPlaceboTotal
Australia171835
China4913
Denmark71017
France459
Germany231639
Japan151833
Netherlands7815
Romania10717
South Korea141731
Spain453075
United Kingdom11920
United States494089
08

Study locations

112 sites

Showing the first 100 of 112 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Smith M, Piulats J, Todenhofer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Flechon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N; CYCLONE 2 investigators. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025 Nov;26(11):1489-1500. doi: 10.1016/S1470-2045(25)00475-9. PubMed 41167216 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jan 2024, 61 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's 61 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2018
First posted
Oct 16, 2018
StartActual
Nov 26, 2018
Primary completionActual
Jan 2, 2024
CompletionEst.
Dec 2026
Results first posted
Mar 6, 2025
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03706365
Responsible party
Sponsor
First posted
Oct 16, 2018
Start date
Nov 26, 2018
Primary completion
Jan 2, 2024
Completion
Dec 2026 (estimated)
Results posted
Mar 6, 2025
Last update
Aug 7, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion